PHARMACOKINETICS

Absorption: The rate of absorption of Etoricoxib is moderate when given orally (the maximum plasma drug concentration occurs after approximately 1 hour), and the extent of absorption is similar with oral and intravenous doses.
Bioavailability: 100% following oral administration
Protein binding: 92%
Metabolism: Hepatic, primarily via cytochrome P450 (CYP) 3A4 isoenzyme
Half life: 20 hours
Elimination: Etoricoxib is eliminated following biotransformation to carboxylic acid and glucuronide metabolites that are excreted in urine and faeces, with little of the drug (<1%) being eliminated unchanged in the urine.

PHARMACODYNAMICS
Etozox inhibits prostaglandin synthesis via inhibition of cyclooxygenase-2 (COX-2) which inhibits the pain, fever and inflammation.

- Osteoarthritis
- Rheumatic arthritis
- Acute gouty arthritis
- Post- operative dental pain
- Primary dysmenorrhea
- Chronic low back pain
- Ankylosing spondylitis

The recommended dose of Etozox is 90 mg once a day.

- Dry mouth
- Taste disturbances
- Mouth ulcers
- Flatulence
- Constipation
- Appetite and weight changes
- Chest pain
- Fatigue
- Paresthesia
- Myalgia
- Rash
- Blurred vision
- Insomnia
- Muscle cramps
- Cold/flu
- Dizziness
- Epistaxis
- Dyspnoea
- Weakness or loss of strength
- Hypertension
- Anxiety
- Headache

- Allergic disorders
- Renal impairment
- Cardiac disease
- Hepatic impairment